Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development
China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...
CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...
Viatris Reports Q4 2022 Results, Highlights China Growth
US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...
China Performs First AB-BNCT Procedures Outside Japan
The first accelerator-based boron neutron capture therapy (AB-BNCT) procedures have been performed in China by...
HutchMed Reports 2022 Financial Results with Revenue Growth
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...
3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease
China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine...
3SBio Terminates Distribution Agreement with AstraZeneca for Byetta
China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...
JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
FibroGen Reports Q4 2022 Financial Results with Revenue Growth
US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global...
China Issues New Ethical Review Measures for Life Sciences and Medical Research
The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration...
Bayer Reports 2022 Sales Growth, Highlights New Drug Performances
Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...
China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access
The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1,...
China’s State Council Unveils Plan for TCM Revitalization and Development
The State Council has released the “Traditional Chinese Medicine (TCM) Revitalization and Development Major Projects...
Topchoice Medical to Acquire 19% Stake in Heren Health for $72.2M
China-based Topchoice Medical Investment Corp., (SHA: 600763) a leading medical service group, is set to...
Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations
China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B...
RinuaGene Raises $14.4M in Pre-Series A+ for mRNA Drug Development
RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100...
Junshi Biosciences Reports 2022 Preliminary Earnings with Revenue Decline
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...
Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...